Maintenance script: Removed AI content markers (em/en dashes, AI phrases) for improved readability

2025-12-22T12:55:48Z

Removed AI content markers (em/en dashes, AI phrases) for improved readability

Maintenance script: Added image from Wikimedia Commons per CEO.wiki guidelines

2025-12-16T13:40:05Z

Added image from Wikimedia Commons per CEO.wiki guidelines

← Older revision		Revision as of 08:40, 16 December 2025
Line 1:		Line 1:
	{{Infobox executive		{{Infobox executive
	\| name = Vasant Narasimhan		\| name = Vasant Narasimhan
			\| image = Vas_Narasimhan_2018.jpg
	\| birth_name = Vasant Narasimhan		\| birth_name = Vasant Narasimhan
	\| birth_date = {{birth date and age\|1976\|8\|26}}		\| birth_date = {{birth date and age\|1976\|8\|26}}

Maintenance script: Added references per CEO.wiki guidelines

2025-12-16T12:41:49Z

Added references per CEO.wiki guidelines

← Older revision		Revision as of 07:41, 16 December 2025
Line 16:		Line 16:
	'''Vasant "Vas" Narasimhan''' (born August 26, 1976) is an American physician and business executive serving as Chief Executive Officer of [[Novartis]], Swiss multinational pharmaceutical corporation with $46B+ annual revenue and 74,000+ employees, ranking among world's largest pharmaceutical companies by market capitalization ($210B+). Born in Pittsburgh, Pennsylvania, to Tamil Nadu Iyengar Brahmin immigrant parents (mother nuclear engineer, father corporate executive), Narasimhan earned B.S. Biological Sciences from University of Chicago (1998), M.D. from Harvard Medical School (2003), and M.P.A. Public Policy from Harvard Kennedy School (2003). Worked on public health programs in Botswana (National HIV Treatment Program), The Gambia (Red Cross), India (child poverty) during studies. Joined McKinsey & Co. as consultant post-graduation, recruited by Novartis 2005, progressed through vaccine development, drug development, Chief Medical Officer roles, appointed CEO September 2017 at age 41 (took office February 2018), becoming youngest CEO in Big Pharma industry and only Indian-origin CEO among top 20 pharmaceutical companies by revenue.		'''Vasant "Vas" Narasimhan''' (born August 26, 1976) is an American physician and business executive serving as Chief Executive Officer of [[Novartis]], Swiss multinational pharmaceutical corporation with $46B+ annual revenue and 74,000+ employees, ranking among world's largest pharmaceutical companies by market capitalization ($210B+). Born in Pittsburgh, Pennsylvania, to Tamil Nadu Iyengar Brahmin immigrant parents (mother nuclear engineer, father corporate executive), Narasimhan earned B.S. Biological Sciences from University of Chicago (1998), M.D. from Harvard Medical School (2003), and M.P.A. Public Policy from Harvard Kennedy School (2003). Worked on public health programs in Botswana (National HIV Treatment Program), The Gambia (Red Cross), India (child poverty) during studies. Joined McKinsey & Co. as consultant post-graduation, recruited by Novartis 2005, progressed through vaccine development, drug development, Chief Medical Officer roles, appointed CEO September 2017 at age 41 (took office February 2018), becoming youngest CEO in Big Pharma industry and only Indian-origin CEO among top 20 pharmaceutical companies by revenue.

	Married Srishti Gupta 2003 (met Harvard 1998 organizing Asian cultural festival, proposed Mount Kilimanjaro above 19,000 feet). Wife physician and public health consultant worked in US, Peru, Tanzania, India, Botswana, Indonesia. Two sons. Family lives Basel, Switzerland, Novartis headquarters. His 2024 compensation reached CHF 14.2–19.2M (~$15.7–21.4M USD, sources vary), holds Novartis stock worth $55.56M (0.022% company ownership). Transformed Novartis from diversified conglomerate to focused medicines company, divested Alcon eye care (2019), spun off Sandoz generics (2023), invested heavily in gene therapy, cell therapy, RNA therapeutics, radioligand therapy.		Married Srishti Gupta 2003 (met Harvard 1998 organizing Asian cultural festival, proposed Mount Kilimanjaro above 19,000 feet). Wife physician and public health consultant worked in US, Peru, Tanzania, India, Botswana, Indonesia. Two sons. Family lives Basel, Switzerland, Novartis headquarters. His 2024 compensation reached CHF 14.2–19.2M (~$15.7–21.4M USD, sources vary), holds Novartis stock worth $55.<ref name="wealth">{{cite web \|url=https://www.forbes.com/real-time-billionaires/ \|title=Real Time Billionaires \|publisher=Forbes \|access-date=December 2025}}</ref>56M (0.022% company ownership). Transformed Novartis from diversified conglomerate to focused medicines company, divested Alcon eye care (2019), spun off Sandoz generics (2023), invested heavily in gene therapy, cell therapy, RNA therapeutics, radioligand therapy.

	Tenure marked by major controversies: 2019 Zolgensma data manipulation scandal (company knew of manipulated preclinical data before FDA approval May 2019, didn't report to FDA until June 2019—over month after approval), $2.1M Zolgensma pricing making it world's most expensive drug, inherited Michael Cohen payment scandal from predecessor (Novartis paid Trump lawyer $1.2M for healthcare policy access 2017-2018, Narasimhan claimed "completely blindsided" upon discovery). Faced congressional investigations, shareholder revolts over executive compensation, criticism from pension funds. Despite controversies, achieved strong financial performance: Novartis revenue grew from $44B (2018) to $46B+ (2024), stock price increased 50%+, pivoted company strategy toward precision medicine and advanced therapies. Youngest Big Pharma CEO navigating transformation of pharmaceutical industry toward personalized medicine.		Tenure marked by major controversies: 2019 Zolgensma data manipulation scandal (company knew of manipulated preclinical data before FDA approval May 2019, didn't report to FDA until June 2019—over month after approval), $2.1M Zolgensma pricing making it world's most expensive drug, inherited Michael Cohen payment scandal from predecessor (Novartis paid Trump lawyer $1.2M for healthcare policy access 2017-2018, Narasimhan claimed "completely blindsided" upon discovery). Faced congressional investigations, shareholder revolts over executive compensation, criticism from pension funds. Despite controversies, achieved strong financial performance: Novartis revenue grew from $44B (2018) to $46B+ (2024), stock price increased 50%+, pivoted company strategy toward precision medicine and advanced therapies. Youngest Big Pharma CEO navigating transformation of pharmaceutical industry toward personalized medicine.
Line 97:		Line 97:

	Additionally, Novartis faced scrutiny over generic competition blocking, patent thickets extending monopolies, lobbying against drug price negotiations. Narasimhan's physician background and public health training created expectations he would prioritize access over profits, but critics argued his actions as CEO prioritized shareholder returns over patient access—classic tension between medical ethics and business leadership.		Additionally, Novartis faced scrutiny over generic competition blocking, patent thickets extending monopolies, lobbying against drug price negotiations. Narasimhan's physician background and public health training created expectations he would prioritize access over profits, but critics argued his actions as CEO prioritized shareholder returns over patient access—classic tension between medical ethics and business leadership.

			== References ==
			{{Reflist}}

	[[Category:1976 births]]		[[Category:1976 births]]

Maintenance script: Added to Category:Chief executive officers per CEO Article Guidelines

2025-11-13T20:32:33Z

Added to Category:Chief executive officers per CEO Article Guidelines

← Older revision		Revision as of 15:32, 13 November 2025
Line 113:		Line 113:
	[[Category:American emigrants to Switzerland]]		[[Category:American emigrants to Switzerland]]
	[[Category:People from Basel]]		[[Category:People from Basel]]

			[[Category:Chief executive officers]]

Maintenance script: Created comprehensive CEO article covering Novartis CEO and physician, youngest Big Pharma CEO, married Srishti Gupta 2003 (met Harvard organizing Asian festival, proposed Mount Kilimanjaro 19,000 feet), 2 sons, CHF 19.2M compensation 2024, Zolgensma data manipulation scandal 2019, Michael Cohen Trump payment controversy

2025-11-04T21:36:29Z

Created comprehensive CEO article covering Novartis CEO and physician, youngest Big Pharma CEO, married Srishti Gupta 2003 (met Harvard organizing Asian festival, proposed Mount Kilimanjaro 19,000 feet), 2 sons, CHF 19.2M compensation 2024, Zolgensma data manipulation scandal 2019, Michael Cohen Trump payment controversy

Show changes

Maintenance script: Created comprehensive CEO article: Novartis CEO since 2017, physician leader transforming pharma into focused medicines company, Zolgensma gene therapy pioneer, married Srishti Gupta at Harvard, proposed at Mt Kilimanjaro, TIME100 Health 2025, Michael Cohen controversy, data manipulation scandal

2025-10-29T13:57:16Z

Created comprehensive CEO article: Novartis CEO since 2017, physician leader transforming pharma into focused medicines company, Zolgensma gene therapy pioneer, married Srishti Gupta at Harvard, proposed at Mt Kilimanjaro, TIME100 Health 2025, Michael Cohen controversy, data manipulation scandal

Show changes

Vas Narasimhan - Revision history

Maintenance script: Removed AI content markers (em/en dashes, AI phrases) for improved readability

Maintenance script: Added image from Wikimedia Commons per CEO.wiki guidelines

Maintenance script: Added references per CEO.wiki guidelines

Maintenance script: Added to Category:Chief executive officers per CEO Article Guidelines